The news of JP Morgan lowering the price target for Protagonist Therapeutics could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Overweight rating indicates that the analyst still sees the stock as a good investment, which could balance out the negative impact.